Craft

MaxCyte

Stock Price

$3.6

2024-10-29

Market Capitalization

$387.9 M

2024-10-29

Revenue

$33 M

FY, 2025

MaxCyte Summary

Company Summary

Overview
MaxCyte (formerly known as Theramed) is a cell engineering company focused on providing platform technologies for cell-based research as well as cell therapeutic discovery, development, and commercialization. It offers the ExPert platform based on its flow electroporation technology, which facilitates the complex engineering of cells. The company also develops the CARMA platform that enables the manufacturing of chimeric antigen receptor (CAR) therapies for a range of cancer indications.
Type
Public
Status
Active
Founded
1998
HQ
Gaithersburg, MD, US | view all locations
Website
https://www.maxcyte.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Doug Doerfler

    Doug Doerfler, President and Chief Executive Officer, Director

  • Richard Douglas

    Richard Douglas, Non-Executive Chairman

    • Ron Holtz

      Ron Holtz, Chief Financial Officer

    • Yasir Al-Wakeel

      Yasir Al-Wakeel, Non-Executive Director

      LocationsView all

      2 locations detected

      • Gaithersburg, MD HQ

        United States

        22 Firstfield Road, Suite 110

      • Alderley Edge, England

        United Kingdom

        Alderley Park

      MaxCyte Financials

      Summary Financials

      Revenue (FY, 2025)
      $33.0M
      Gross profit (FY, 2025)
      $26.8M
      Net income (FY, 2025)
      ($44.6M)
      Cash (FY, 2025)
      $20.1M
      EBIT (FY, 2025)
      ($51.9M)
      Enterprise value
      $385.8M

      Footer menu